Skip to main content
Clinical Trials/NCT05646056
NCT05646056
Completed
Not Applicable

A Noninterventional, Single-Center Feasibility Study to Evaluate Longitudinal Measures of Heart Failure Risk Using the Pyxida System

Prolaio1 site in 1 country82 target enrollmentOctober 28, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Prolaio
Enrollment
82
Locations
1
Primary Endpoint
To evaluate the ability of the Pyxida System to collect measurements of heart failure (HF) risk
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a non-invasive/observational study in healthy and mild HF subjects utilizing clinical and ambulatory measurements to improve detection, monitoring, and management of HF risks.

Registry
clinicaltrials.gov
Start Date
October 28, 2022
End Date
September 18, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Prolaio
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Cohort 2: Confirmed medical history of LVH based on American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and NYHA Class I at screening
  • Cohort 3: Confirmed medical history of HF consistent with current ACC/AHA guidelines and NYHA Class I at screening
  • Cohort 4: Confirmed medical history of HCM consistent with ACC/AHA guidelines and NYHA Class I or II at screening

Exclusion Criteria

  • Active neurological disorder, such as uncontrolled seizure disorder.
  • Current diagnosis of cancer or other known acute chronic infection, such as hepatitis B or hepatitis C, by medical history or an active infection requiring interventional therapy at screening.
  • Shortness of breath, fatigue, heart palpitations, pain, or other limitations of physical activity

Outcomes

Primary Outcomes

To evaluate the ability of the Pyxida System to collect measurements of heart failure (HF) risk

Time Frame: 14 days

Percentage of complete daily datasets transmitted to the Pyxida System database at the end of the monitoring period

Secondary Outcomes

  • To evaluate subject compliance and experience using the Pyxida System(14 days)

Study Sites (1)

Loading locations...

Similar Trials